Nijmegen

• Phase II Dutasteride in combination with CAB vs CAB in SDC (DUCT) Recruiting
  2022-500745-24-00 10 2022-09-20 Salivary Duct Carcinoma
• Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study Recruiting
  2024-515528-35-00 11 2022-09-08 Congenital Haemophilia A
• A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia Recruiting
  2023-503335-18-00 1 2022-07-29 Chronic myeloid leukemia
• A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan … Recruiting
  2023-504660-41-00 4 2022-07-11 Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (PBC
• Treatment of opioid dependency in patients with chronic pain: a comparative study between suboxone and methadone. Recruiting
  2024-513924-41-01 6 2022-05-11 Opioid use disorder (DSM-5); chronic non-cancer pain (ICD-11).
• Pancreatitis and early omega-3-fatty acid infusion for reduction of organ failure and mortality. Recruiting
  2023-505220-57-03 5 2022-05-09 Predicted severe acute pancreatitis
• A study of MK-7240/PRA023 in patients with Systemic Sclerosis Associated with Interstitial Lung Disease Recruiting
  2023-509743-27-00 4 2022-04-29 Systemic sclerosis associated with interstitial lung disease
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: a randomized multi-center study in resectable HER2 … Recruiting
  2024-513797-22-00 5 2022-03-09 HER2 positive esophageal adenocarcinoma
• Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants with Myotonic Dystrophy Type 1 Recruiting
  2023-510353-42-00 7 2022-02-21 Myotonic Dystrophy Type 1
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. Recruiting
  2023-505497-14-00 4 2021-12-09 Proteinuric glomerular diseases including: •Focal segmental glomerulo
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• FIGO 2018 stage IB2 (>2 cm - ≤4 cm ) Cervical Cancer Treated with Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery (CoNteSSa) … Recruiting
  2023-507230-24-00 4 2021-02-17 Cervical cancer
• A First-in-Human Study to Evaluate the Safety and Anti-cancer Activity of the product FS222, which is an Antibody medication, in Subjects wi … Recruiting
  2024-514010-12-00 1 2020-12-03 Advanced Malignancies
• GROINSS-V III Recruiting
  2023-508722-99-00 4 2020-11-19 Vulvar cancer
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other … Recruiting
  2024-510783-23-00 7 2020-10-29 Fallopian Tube Cancer
• Multicentre, open-label, randomized, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus … Recruiting
  2024-512526-28-00 5 2020-10-28 Locally recurrent rectal cancer
• Doxapram versus placebo in preterm newborns: An international double blinded multicenter randomized controlled trial Recruiting
  2024-515625-29-00 5 2020-06-16 Apnea of prematurity
• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 11 2019-10-28 C3 Glomerulopathy or idiopathic immune-complex membranoproliferative g
• SGM-LARRC: Multicenter, open-label, controlled, parallel arms clinical study on the performance of SGM-101, a fluorochrome-labeled anti-carc … Recruiting
  2024-510768-21-00 4 2019-10-16 Rectal cancer
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting
  2024-513627-16-01 7 2018-03-28 Colorectal cancer metastatic

Showing 289–312 of 568 trials